Immunotherapy with Allergen Peptides

Table 1 Clinical studies of peptide immunotherapy in allergy.

*Allergen*	*Peptide Characteristics*	*Study Design*	*Number of Subjects*	*Route of Administration*	*Total Dose (μg)*	*Clinical Outcomes*	*Reference*
Fel d 1 (cat)	2 × 27mer	DBPC	95	SC	30-3,000	Nasal and lung symptoms	[43]
	2 × 27mer	Open		SC	150-4,500	Allergen PD₂₀	[46]
	2 × 27mer	DBPC	42	SC	1,000	End-point titration, skin LPR	[47]
	2 × 27mer	DBPC	133	SC	600-6,000	FEV₁,* daily peak flow, skin EPR, symptom assessment	[48]
	3 × 16/17mer	Open	6	ID	80	Isolated LAR	[44]
	12 × 16/17mer	Open	8	ID	5	Isolated LAR and skin LPR	[49]
	12 × 16/17mer	DBPC	24	ID	90	Skin LPR and EPR, PC₂₀, PD₂₀	[50]
	11 × 16/17mer	Open	8	ID	41.1	Skin LPR, PC₂₀	[51]
	12 × 16/17mer	DBPC/open	28	ID	216-341	Nasal allergen challenge, bronchial challenge, skin LPR	[53]
Api m 1(PLA₂) (bee)	1 × 11, 1 × 12, 1 × 18	Open	5	SC	397.1	Skin challenge PLA₂, bee sting	[55]
	1 × 60, 1 × 53, 1 × 45	DBPC	16	SC	751.1	End-point skin titration	[58]
	4 × 18	Open-controlled	24	ID	431.1	Skin LPR	[57]

DBPC = double-blind placebo controlled; EPR = early-phase reaction; FEV₁ = forced expiratory volume in 1 second; ID = intradermal; LAR = late asthmatic reaction; LPR = late-phase reaction; PC₂₀ = provocative concentration of histamine that induces a 20% reduction in FEV₁; PD₂₀ = provocative dose of inhaled allergen resulting in a 20% reduction in forced expiratory volume in 1 second; PLA₂ = phospholipase A₂; SC = subcutaneous.
*Only in subjects with reduced baseline FEV1 and only at one time point.

ISSN: 1710-1492